New Amsterdam is developing obicetrapib, a cholesteryl ester transfer protein (CETP) inhibitor aimed at lowering low-density lipoprotein cholesterol (LDL-C) levels in patients with cardiovascular disease and lipid-related conditions. The company targets the significant unmet need for effective lipid-lowering therapies that can help patients achieve their LDL-C goals and reduce cardiovascular risk.
Funding
Funding not disclosed
Founders
Product
Problem
Many patients with cardiovascular disease and lipid-related conditions still struggle to achieve recommended low-density lipoprotein cholesterol (LDL-C) goals despite existing lipid-lowering therapies. This unmet need leaves them at increased cardiovascular risk.
Solution
NewAmsterdam Pharma is developing obicetrapib, an investigational cholesteryl ester transfer protein (CETP) inhibitor, as a novel approach to address this unmet need. Obicetrapib is designed to lower LDL-C levels and, consequently, reduce cardiovascular risk in patients who are unable to reach their LDL-C targets with current treatments. The company's focus is on advancing treatments for cardiovascular disease and other lipid-related conditions, aiming to reduce the global impact of cardiovascular disease. Clinical trials are underway to evaluate obicetrapib's efficacy and safety.
Target Audience
The primary target audience includes patients with cardiovascular disease and lipid-related conditions, particularly those with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who are not reaching their LDL-C goals with current therapies.
Features
- Obicetrapib: A CETP inhibitor with a novel mechanism of action for lowering LDL-C.
- Investigational asset selected based on its potential to lower LDL-C and reduce cardiovascular risk.
- Fixed-dose combination of obicetrapib 10 mg and ezetimibe 10 mg in development.
- Clinical trials are ongoing, including Phase 3 trials, to assess the efficacy and safety of obicetrapib.